International Journal of
Molecular Microbiology

Opinion 2025 | Volume 8 | Issue 1 | 32-36

Open Access

Article Information

Received: February 5, 2025

Accepted: February 22, 2025

Published: February 28, 2025

Keywords

Biomedicine,
molecular science,
technological innovation,
health artificial intelligence,
precision medicine.

Authors' Contribution

AJA designed the study; wrote and revised the paper.

How to cite

Alkhatib, A.J., 2025. Emerging Frontiers in Biomedicine: A 2025 Outlook on Transformative Research Themes. Int. J. Mol. Microbiol., 8(1): 32-36.

***Correspondence**

Ahed J Alkhatib
Email:
ajalkhatib@just.edu.jo

Emerging Frontiers in Biomedicine: A 2025 Outlook on Transformative Research Themes

Ahed J Alkhatib*[1,2,3]

[1]Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science & Technology, Jordan.
[2]International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology.
[3]Cypress International Institute University, Texas, USA.

Abstract:
Biomedicine is developing quickly, as a result of technological innovation, molecular science and computing power. Hot topics for research, grant applications and translation effort in the year 2025. This paper illustrates some of the fastest growing fields of biomedicine including the area of health artificial intelligence, genomics and precision medicine, regenerative therapies, cancer immunotherapy, the microbiome and neurobiological interfaces. Each theme is scientifically underpinned, clinically applicable, ethically considered and future proofed. This synthesis will give researchers, clinicians, and policymakers a strategic perspective on where biomedicine might go, and what public health and personalized medicine benefits these advances might offer.

Scan QR code to visit this journal.

INTRODUCTION

The use of Artificial Intelligence (AI) is no longer theoretical, but rather comes with various AI implementations in clinical settings. Through large datasets, machine learning algorithms predict the risk of disease, identify anomalies in imaging, and help in a diagnosis. In drug discovery pipelines, alpha fold-type generative AI models are becoming a key tool for protein structure prediction (Jumper *et al.,* 2022).

AI clinical decision support systems help improve diagnosis and personalize treatment strategies. Wearable biosensors and health apps let doctors get accurate patient data in real-time (Topol, 2019). Diabetes patients may be given continuous glucose monitors, ECG patches or smartwatches to improve metabolic function and heart rate.

Health practitioners are trying out patient digital twins to personalize medical treatments for their patients (Bruynseels *et al.,* 2018; Iqbal and Ashraf, 2024; Iqbal, 2024a). Data privacy, algorithmic bias and regulatory oversight pose ethical challenges (Wiens *et al.,* 2019; Alkhatib and Darabseh, 2025). Synthetic biology helps scientists quickly create new drugs and tests to fight diseases.

Genomics and precision medicine

The price for sequencing a human genome has dropped dramatically. This has made large-scale efforts like the All of Us Research Program, and the UK Biobank possible to explore the genetic component of disease (Sudlow *et al.,* 2015). Risk assessments for cardiovascular disease, diabetes and psychiatric disorders incorporate polygenic risk scores (Torkamani *et al.,* 2018).

The clinical trials for sickle cell disease, thalassemia, and certain cancers now involve gene-editing tools of CRISPR-Cas (Frangoul *et al.,* 2021). New base and prime editing technologies work much more accurately and with less disruption to the cell (Anzalone *et al.,* 2019). Drug treatment has moved from a one-size-fits-all to an individualistic treatment recently due to Pharmacogenomics (Relling and Evans, 2015).

Regenerative medicine and stem cell therapies

Regenerative medicine is using stem cells, biomaterials, and growth factors to restore or replace damaged tissues (Ali *et al.,* 2016; Iqbal, 2019; 2020; 2024b; Iqbal and Ashraf, 2025). As noted by Takahashi et al. (2007), early Phase Clinical Trials related to macular degeneration, spinal cord injury and repair of heart have arisen through induced pluripotent stem cells (iPSCs), which are now widely used in modelling disease.

The scaffolds of living cells enable fast 3D bioprinting of tissues and organs (Murphy and Atala, 2014) by using quick 3D bioprinting. Bioengineered products like skin and cartilage are clinically used. Lab-grown organoids (Lancaster and Knoblich, 2014), which are tiny organs, are increasingly employed in drug screening and developmental biology.

Immunotherapy and cancer virotherapy

Oncology or cancer treatment uses drug or radiation therapy to kill the cancerous cells (Din *et al.,* 2016; Irfan *et al.,* 2016). Several mutations were correlated with poor overall survival in cancer patients (Ashraf *et al.,* 2018). CheckPoint inhibitors have durable responses in several cancers with PD-1 and CTLA-4 (Sharma and Allison, 2015).

CAR T-cells were approved for blood cancers (hematologic malignancies) and are increasingly also being applied to solid tumors (Maude *et al.,* 2018). Oncolytic virotherapy is the treatment that involves the use of a virus that is modified to kill cancer cells. It is starting to become popular (Russell *et al.,* 2012).

The human microbiome and metabolic health

Microbiome studies are moving from correlation to causation. Microbial communities are now being viewed as players involved in immunity, metabolism and neurobiology (Lloyd-Price *et al.,* 2016; Alkhatib, 2018). A disrupted microbiota or dysbiosis is connected with obesity, diabetes, IBD and colonic cancer (Turnbaugh *et al.,* 2006).

The FDA now approves fecal transplants for *Clostridioides difficile* although the infection is difficult to treat (van Nood *et al.,* 2013). People are working on custom-made probiotics. Researchers are looking into the microbiome-derived metabolites for therapeutic targeting (Nicholson *et al.,* 2012).

Neurotechnology and brain-machine interfaces

According to Lebedev and Nicolelis (2006), brain-computer interfaces (BCIs) are arising increasingly for restoring communication and movement to people with severe motor impairments. Non-invasive neurotechnologies are on the rise in clinics. Researchers are looking into the relationship between autism and the gut-brain axis (Cryan *et al.,* 2019; Alkhatib, 2024). Neuroethics is a growing field that looks at issues like consent and enhancement (Farah, 2012).

Inflammation, aging, and chronic disease

Chronic low-grade inflammation, also called "inflammaging", is a common denominator of biological aging and many noncommunicable diseases (Franceschi *et al.,* 2018). Human testing on senolytic drugs to kill senescent cells has begun (Xu *et al.,* 2018). Cardiovascular and metabolic disease risk stratification involves the inflammatory biomarkers.

Psychedelic medicine and neuropharmacology

Psychedelics have an effect on depression, PTSD, and addiction like psilocybin, MDMA and ketamine (Carhart-Harris and Goodwin, 2017). Psychedelics improve neural connections and enhance brain activity in the part of the brain which is not involved in the immediate cognitive goal. We are doing research on psychedelic therapies (Alkhatib, 2025).

Climate change, emerging diseases, and global health preparedness

Climate change is accelerating infectious disease spread (Iqbal and Ashraf, 2023). According to Ryan et al. (2019), there has been a rise in vector-borne diseases such as dengue and Zika. We need tools to help the scientists' research antibiotic resistance amid rising antibiotic resistance (O'Neill, 2016; Ashraf *et al.,* 2020; Ashraf and Iqbal, 2020; 2022). mRNA vaccine platforms enable quick reaction to new pathogens (Pardi *et al.,* 2018).

CONCLUSION

Biomedicine in 2025 will be significantly influenced by convergence. Molecular biology incorporates AI, classical pharmacology intertwines with immunology, and personalized care supersedes standardization. Even with various developments, the impact does not go far beyond the ethical challenges. To ensure global health worldwide biomedical innovation that has the potential to be harnessed, a multidisciplinary approach with scientists, clinicians, engineers, ethicists and policy makers is needed.

CONFLICT OF INTEREST

The author hereby declares no conflict of interest.

REFERENCES

Ali, S., Ahmad, A., Iqbal, M.N., Muhammad, A., Irfan, M., Akhter, S., 2016. Opportunities for Stem Cells Therapy in Veterinary Medicine. PSM Vet. Res., 01(2): 60-68.

Alkhatib, A.J., 2018. Non-classical Roles of Microbes. PSM Microbiol., 3(2): 62-63.

Alkhatib, A.J., 2024. The New Frontier of Medicine: The Brain and the Gut. PSM Vet. Res., 9(1): 1–3.

Alkhatib, A.J., 2025. The Role of Psychedelics in Treating Mental Health Disorders: A Mini-Review. PSM Biol. Res., 10(1), 10–17.

Alkhatib, A. J., Darabseh, R.S., 2025. Ethical Challenges in AI-driven Healthcare

Innovations. Int. J. New Med., 1(1): 11–27.

Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L.W., Levy, J.M., Chen, P.J., Wilson, C., Newby, G.A., Raguram, A., Liu, D.R., 2019. Search-and-replace genome editing without double-strand breaks or donor DNA. Nat., 576(7785): 149–157.

Ashraf, A., Iqbal, M.N., 2020. Tracking the Effectiveness of Antibiotic Therapy using the Drug Resistance Profile of Uropathogens in Pregnant Women. PSM Biol. Res., 5(4): 178-180.

Ashraf, A., Iqbal, M.N., 2022. Antibacterial Compounds from Ethanolic Extract of *Scenedesmus obliquus* as Alternatives to Antibiotics. Int. J. Altern. Fuels. Energy., 6(1): 12-14.

Ashraf, A., Xiong, X., Iqbal, M.N., Lin, Y., 2018. BRCA Mutations and Survival Outcome in Young-onset Breast Cancer. Int. J. Mol. Microbiol., 1(2): 56-57.

Ashraf, A., Iqbal, M.N., Iqbal, A., 2020. The Rise of Antibiotic Resistance in Clinical Isolates of Bacteria: An Emerging Public Health Problem. Int. J. Mol. Microbiol., 3(1): 15-17.

Bruynseels, K., Santoni de Sio, F., van den Hoven, J., 2018. Digital twins in health care: Ethical implications of an emerging engineering paradigm. Front. Genet., 9: 31.

Carhart-Harris, R.L., Goodwin, G.M., 2017. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacol., 42(11): 2105–2113.

Cryan, J.F., O'Riordan, K.J., Cowan, C.S., et al. 2019. The microbiota-gut-brain axis. Physiol. Rev., 99(4): 1877–2013.

Din, M., Hafeez, M., Iqbal, M.N., Ashraf, A., Alam, S., Masood, S., 2016. Parameters of Radiotherapy Techniques in Early Breast Cancer. PSM Microbiol., 01(2): 66-71.

Farah, M.J., 2012. Neuroethics: The ethical, legal, and societal impact of neuroscience. Ann. Rev. Psychol., 63: 571–591.

Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., Santoro, A., 2018. Inflammaging: A new immune–metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol., 14(10): 576–590.

Frangoul, H., Altshuler, D., Cappellini, M.D., Chen, Y.S., Domm, J., Eustace, B.K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T.W., 2021. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New Engl. J. Med., 384(3): 252–260.

Iqbal, M.N., Ashraf, A., 2023. Global Climate Change Impacts Health, Environment and Economy. Int. J. Altern. Fuels. Energy., 7(2): 34-6.

Iqbal, M.N., Ashraf, A., 2024. The Potential of Digital Therapeutics in Healthcare to Improve Patient Outcomes. PSM Vet. Res., 9(1): 18-20.

Iqbal, M.N., Ashraf, A., 2025. The Potential of mRNA-based Therapeutics in the Management of Infectious Diseases. Int. J. New Med., 1(1): 34-36.

Iqbal, M.N., 2019. Recent Developments and Future Prospects of Gold Nanoparticles in Biomedicine and Diagnostics. Int. J. Nanotechnol. Allied Sci., 3(2): 40-44.

Iqbal, M.N., 2020. COVID-19 Pandemic: The Potential Role of Nanotechnology and Nanomedicine in Vaccine Development. Int. J. Nanotechnol. Allied Sci., 4(2): 44-46.

Iqbal, M.N., 2024a. Digital Therapeutics: A Major Revolution in the Management of Chronic Diseases. PSM Vet. Res., 9(1): 21-3.

Iqbal, M.N., 2024b. Nanoformulations in Medicine: Current Trends, Future Directions and Implications for Public Health. Int. J. Nanotechnol. Allied Sci., 8(2): 40-42.

Irfan, M., Sughra, K., Iqbal, M.N., Mehmood, S., Shaheen, A., Anwar, Z., 2016. Arresting Cancer Progression by VEGF Inhibitions: An Update. PSM Microbiol., 01(2): 72-78.

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., 2021. Highly accurate protein structure prediction with AlphaFold. Nat., 596(7873): 583–589.

Lancaster, M.A., Knoblich, J.A., 2014. Organogenesis in a dish: Modeling development and disease using organoid technologies. Sci., 345(6194): 1247125.

Lebedev, M.A., Nicolelis, M.A., 2006. Brain–machine interfaces: Past, present and future. Trends. Neurosci., 29(9): 536–546.

Lloyd-Price, J., Abu-Ali, G., Huttenhower, C., 2016. The healthy human microbiome. Gen. Med., 8(1): 51.

Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D., Qayed, M., 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl. J. Med., 378(5): 439–448.

Murphy, S.V., Atala, A., 2014. 3D bioprinting of tissues and organs. Nat. Biotechnol., 32(8): 773–785.

Nicholson, J.K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., Pettersson, S., 2012. Host-gut microbiota metabolic interactions. Sci., 336(6086): 1262–1267.

O'Neill, J., 2016. Tackling drug-resistant infections globally: Final report and recommendations. 84-pp.

Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D., 2018. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Disc., 17(4): 261–279.

Relling, M.V., Evans, W.E., 2015. Pharmacogenomics in the clinic. Nat., 526(7573): 343–350.

Russell, S.J., Peng, K.W., Bell, J.C., 2012. Oncolytic virotherapy. Nat. Biotechnol., 30(7): 658–670.

Ryan, S.J., Carlson, C.J., Mordecai, E.A., Johnson, L.R., 2019. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl. Trop. Dis., 13(3): e0007213.

Sharma, P., Allison, J.P., 2015. The future of immune checkpoint therapy. Sci., 348(6230): 56–61.

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., 2015. UK Biobank: An open access resource. PLoS Med., 12(3): e1001779.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts. Cell., 131(5): 861–872.

Topol, E.J., 2019. High-performance medicine: The convergence of human and artificial intelligence. Nat. Med., 25(1): 44–56.

Torkamani, A., Wineinger, N.E., Topol, E.J., 2018. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet., 19(9): 581–590.

Turnbaugh, P. J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., 2006. An obesity-associated gut microbiome. Nat., 444(7122): 1027–1031.

van Nood, E., Vrieze, A., Nieuwdorp, M., et al. 2013. Duodenal infusion of donor feces for recurrent C. difficile. New Engl. J. Med., 368(5): 407–415.

Wiens, J., Saria, S., Sendak, M., Ghassemi, M., Liu, V.X., Doshi-Velez, F., Jung, K., Heller, K., Kale, D., Saeed, M., Ossorio, P.N., 2019. Do no harm: A roadmap for responsible machine learning in health care. Nat. Med., 25(9): 1337–1340.

Xu, M., Pirtskhalava, T., Farr, J.N., et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nat. Med., 24(8): 1246–1256.